Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Qiagen and Bio One Capital have entered into a joint venture to establish Dx Assays, as one of the first centres in Singapore for assay development in which molecular diagnostics for infectious and genetic diseases will be developed.
Subscribe to our email newsletter
The centre is expected to be fully operational by early 2008, employ more than 30 scientists and be equipped with state-of-the-art technology. The new Singapore venture is Qiagen’s latest step in the expansion of its presence in the rapidly growing Asian markets.
Peer Schatz, CEO of Qiagen, said: “The in-depth expertise and talent pool in biomedical research makes Singapore an ideal location for a centre for assay development.”